QR-Code

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia

Abstract Background A Phase II proof of concept (POC) randomized clinical trial was conducted to evaluate the effects of rasagiline, a monoamine oxidase B (MAO‐B) inhibitor approved for Parkinson disease, in mild to moderate Alzheimer's disease (AD). The primary objective was to determine if 1 mg of...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Dawn C. Matthews, Aaron Ritter, Ronald G. Thomas, Randolph D. Andrews, Ana S. Lukic, Carolyn Revta, Jefferson W. Kinney, Babak Tousi, James B. Leverenz, Howard Fillit, Kate Zhong, Howard H. Feldman, Jeffrey Cummings
Format: Artigo
Sprache:Inglês
Veröffentlicht: Wiley 2021-01-01
Schriftenreihe:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Schlagworte:
Alzheimer's disease
dopamine
FDG‐PET
flortaucipir
glucose metabolism
MAO‐B
Online-Zugang:https://doi.org/10.1002/trc2.12106
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge